Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TLX vs APLS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

APLS Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 10–0 Matrix Metrics)

APLS Overall Winner 6-Pillar Tally: TLX 0 – 6 APLS Matrix Metrics: TLX 0 – 10 APLS

As of Nov 16, 2026, Apellis Pharmaceuticals, Inc. (APLS) is the stronger overall head-to-head candidate over Telix Pharmaceuticals Limited (TLX) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TLX carries a Unified Composite Score of 46.4/100 (HOLD) at $8.96 (N/M Forward P/E, 6.2% operating margin), whereas APLS carries 60.2/100 (BUY) at $41.03 (46.3x Forward P/E, 9.9% operating margin).

  • Technical & Structure Timing Caution: TLX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile APLS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 84.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TLX vs APLS
TLX NASDAQ
Telix Pharmaceuticals Limited American Depositary Shares
Pharmaceutical Preparations
$8.96
-2.98% 1D
Market Cap $3.2B
TTM Revenue $891M
Forward P/E N/M
Beta / 30D Vol 0.84β · 62% Vol
Unified Composite Score
46.4 / 100 HOLD
Tech 64.0 Fund 62.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.7%), weak momentum, RSI 39
RSI-14: 39.0 · SMA20: $9.46 · SMA50: $10.61
APLS NASDAQ Head-to-Head Winner
Apellis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$41.03
-0.07% 1D
Market Cap $5.3B
TTM Revenue $1.11B
Forward P/E 46.3x
Beta / 30D Vol 4.54β · 2% Vol
Unified Composite Score
60.2 / 100 BUY
Tech 40.0 Fund 52.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (30.4% over 20 days), RSI 84
RSI-14: 84.5 · SMA20: $40.97 · SMA50: $32.36

6-Pillar Scorecard Institutional Category Breakdown (TLX 0 – 6 APLS)

Columns: Metric · TLX · APLS
1. Valuation Multiples APLS
Forward P/E N/M 46.3x
Trailing P/E 93.6x 38.3x
PEG Ratio N/M N/M
EV / Revenue 3.6x 4.8x
2. Growth & Scale APLS
Revenue Growth (YoY) +22.3% +60.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $891M $1.11B
Market Cap $3.2B $5.3B
3. Profitability & Quality APLS
Gross Margin 47.6% 64.3%
Operating Margin 6.2% 9.9%
Net Profit Margin 3.8% 12.1%
Return on Equity (ROE) 7.4% 46.0%
4. Balance Sheet & Cash Flow APLS
Cash Generation (TTM) $70M EBITDA $167M EBITDA
Cash Flow Margin 7.8% EBITDA Mgn 15.1% EBITDA Mgn
Net Cash / Leverage $1.44 Book/Sh · 7.4% ROE $3.24 Book/Sh · 46.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning APLS
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 0.3% (<1st %ile)
Put/Call OI Skew Thin ADR Chain 0.89x (Balanced)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat APLS
OpEx & R&D Intensity 41.4% of Rev ($369M) 54.4% of Rev ($601M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TLX (0) vs APLS (10)
Institutional Metric TLX APLS Criterion Row Edge
Market Capitalization
Scale
$3.2B $5.3B Larger Scale APLS
Trailing P/E Ratio
Valuation
93.6x 38.3x Lower Multiple APLS
Forward P/E Ratio
Valuation
N/M 46.3x Lower Multiple APLS
Revenue Growth (YoY)
Growth
+22.3% +60.9% Higher Growth APLS
Operating Margin (TTM)
Profitability
6.2% 9.9% Higher Margin APLS
Net Profit Margin
Profitability
3.8% 12.1% Higher Margin APLS
Return on Equity (ROE)
Capital Efficiency
7.4% 46.0% Higher ROE APLS
52-Week Range Position
Momentum
39% ($6–$13) 100% ($16–$41) Stronger Trend APLS
Beta / 30D Volatility
Risk Regime
0.84β · 62% Vol 4.54β · 2% Vol Lower Realized Risk APLS
Unified Institutional Score
Composite Signal
46.4 / 100 (HOLD) 60.2 / 100 (BUY) Higher Composite APLS
Trailing 12M Revenue (USD)
Operating Scale
$891M $1.11B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
47.6% 64.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.6x EV/Rev N/M PEG · 4.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$70M EBITDA ($1.44 Book/Sh · 7.4% ROE) $167M EBITDA ($3.24 Book/Sh · 46.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon APLS +2.12 pp
TLX: -1.68% · APLS: +0.44%
3M Horizon APLS +32.11 pp
TLX: +51.8% · APLS: +83.91%
6M Horizon APLS +96.5 pp
TLX: +10.62% · APLS: +107.12%
1Y Horizon APLS +96.5 pp
TLX: +10.62% · APLS: +107.12%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TLX vs APLS. Trailing 12-month operating profitability (TLX 6.2% vs APLS 9.9%) and valuation multiples (TLX N/M vs APLS 46.3x Forward P/E) are benchmarked directly in Pillar 4 below.

TLX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$891M
Gross Margin47.6%
Op. Margin6.2%
ROE / Fwd P/E7.4% · N/M
APLS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.11B
Gross Margin64.3%
Op. Margin9.9%
ROE / Fwd P/E46.0% · 46.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TLX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
APLS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.3%
IV Percentile <1st %ile
Put/Call OI Skew 0.89x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact APLS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TLX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.2B market capitalization and 6.2% operating margin.
OpEx & R&D Reinvestment 41.4% of Rev ($369M)
90D Engineering Disclosures 0 Published
APLS Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $5.3B market capitalization and 9.9% operating margin.
OpEx & R&D Reinvestment 54.4% of Rev ($601M)
90D Engineering Disclosures 0 Published

Investor FAQ TLX vs APLS Key Questions & Quantitative Answers

As of Nov 16, 2026, Apellis Pharmaceuticals, Inc. (APLS) is the stronger overall head-to-head candidate over Telix Pharmaceuticals Limited (TLX) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TLX carries a Unified Composite Score of 46.4/100 (HOLD) at $8.96 (N/M Forward P/E, 6.2% operating margin), whereas APLS carries 60.2/100 (BUY) at $41.03 (46.3x Forward P/E, 9.9% operating margin). Technical & Structure Timing Caution: TLX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile APLS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 84.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

APLS leads the Growth & Scale pillar: TLX posts +22.3% YoY revenue growth and +0.0% YoY earnings growth on $891M TTM revenue (47.6% gross margin, 6.2% operating margin), compared with APLS at +60.9% YoY revenue growth and +0.0% YoY earnings growth on $1.11B TTM revenue (64.3% gross margin, 9.9% operating margin). On trailing 12-month operating scale, TLX generates $891M in USD-normalized revenue versus $1.11B for APLS. In operating R&D and SG&A reinvestment, TLX deploys 41.4% of Rev ($369M) (0 90-day corporate R&D disclosures) versus 54.4% of Rev ($601M) (0 disclosures) for APLS.

APLS screens cheaper on headline valuation multiples. TLX trades at N/M Forward P/E, 93.6x Trailing P/E, N/M PEG, and 3.6x EV/Revenue (7.8% EBITDA margin), whereas APLS trades at 46.3x Forward P/E, 38.3x Trailing P/E, N/M PEG, and 4.8x EV/Revenue (15.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TLX (7.4% ROE) versus APLS (46.0% ROE) capital efficiency.

In options market volatility and institutional positioning, TLX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.84β · 62% Vol realized risk). By comparison, APLS carries 0.3% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.89x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.54β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Telix Pharmaceuticals Limited American Depositary Shares (TLX) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.